You are here: Industry Insights > Pharma in China

News List

Pharmaceutical Business in China and Worldwide (September)(2023) PharmaSources
October 01, 2023
Pharmaceutical companies reached a cooperation agreement and began to commercialize drugs for the treatment of diseases.
An Overview of the Research Advancements in Bispecific Antibodies Dopine/PharmaSources
August 30, 2023
According to the Pharmacodia Database, currently, there have been 13 drugs approved worldwide in this field. However, Removab was withdrawn from the market in 2017 due to its strong immunogenicity and commercial reasons.
With Whole Line Reduction or R&D Difficulties, Projects of Billions of Dollars Are Stranded - Analysis on Transnational Pharmaceutical Companies Terminating R&D Projects in H1 of the Year PharmaSources/Spuer 203
August 28, 2023
Sales volume of Dupixent reaching USD 5.35 billion in H1 of the year, setting off a R&D boom of IL-4R in China PharmaSources/Yefenghong
August 28, 2023
Under the influence of Dupixent, there is a R&D boom of IL-4 targets in China.
FTC’s Antitrust Intensifies, Where Does Pharmaceutical Innovation Go? PharmaSources/Xiaobing
August 23, 2023
In fact, the FTC has more than once blocked MNC’s mergers and acquisitions under the name of “antitrust”. So, what impact will this have on the US pharmaceutical ecosystem? What challenges does it pose to domestic innovative drugs going global?
35 per 100 CNY Earned for Marketing, How Much is the Sales Expense Ratio of Chinese Pharmaceutical Companies? PharmaSources/Caicai
August 17, 2023
High sales expenses not only increase the cost of medical treatment and medication, but also affect the healthy development of the domestic pharmaceutical industry. Therefore, anti-corruption is imperative and imminent.
Research Progress on the Antitumor Activity of Sesquiterpene Lactone Compounds PharmaSources/Xiaomichong
August 16, 2023
Tumor resistance is a major obstacle in cancer treatment, and increasing evidence suggests that combining natural products with anticancer drugs can achieve better therapeutic effects.
EQRx, known as the "TEMU" of the Pharmaceutical Industry, has been Acquired by Revolution Medicines PharmaSources/Xiaobing
August 15, 2023
EQRx, known as the "TEMU" of the pharmaceutical industry, has been acquired by Revolution Medicines，posing a risk of "returns" for Chinese innovative drugs.
Domestic Enterprises Have Fully Laid out the Blue Ocean of US$10 Billion, and CAR-T Therapy Must Overcome the Achilles' Heel of Solid Tumor 203 Spuer/PharmaSources
August 07, 2023
The solid tumor is one of the two most deeply developed fields in CAR-T therapy, thus it is extremely urgent to overcome solid tumor in CAR-T therapy, considering domestic market access policy and current biomedical capital environment.
Famous GLP-1RA Outside of the Circle, and Rapid Development of Peptide CDMO Xiaobin/PharmaSources
August 07, 2023
With the famous weight-loss drugs are famous outside of the circle, such as GLP-1RA, it has also stimulated the market's demand and concern for peptide CDMO.